Data gathered: June 20
AI Stock Analysis - 23andMe (ME)
Analysis generated November 21, 2024. Powered by Chat GPT.
23andMe, headquartered in Sunnyvale, California, is a genomics and biotechnology company primarily known for offering direct-to-consumer genetic testing services. Founded in 2006, the company has become a significant player in personalized health and ancestry information via genetic data. Their model empowers consumers with access to their genetic information, promoting greater health awareness and fostering interest in ancestry-related information.
Stock Alerts - 23andMe (ME)
 |
23andMe | March 30 App downloads are up by 14.2% in the last couple of days. |
|
23andMe | March 30 News Alert: ‘People should be worried’: 23andMe bankruptcy could expose customers’ genetic data |
|
23andMe | March 28 Price is up by 22.1% in the last 24h. |
|
23andMe | March 27 Price is up by 13.5% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for 23andMe
About 23andMe
23andMe Holding Co. is a publicly held personal genomics and biotechnology company based in South San Francisco, California.
| Price | $0.61 |
| Target Price | Sign up |
| Volume | 27,670,000 |
| Market Cap | $13M |
| Year Range | $0.53 - $5.84 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Jewish genetic data in danger again as 23andMe goes up for saleApril 1 - The Jerusalem Post |
 |
FTC Says 23andMe Purchaser Must Uphold Existing Privacy Policy For Data HandlingApril 1 - Slashdot.org |
 |
23andMe Is Selling All Your Data, in Largest Sale of Genomes in HistoryApril 1 - Biztoc.com |
 |
These are the people who want to buy 23andMeApril 1 - Biztoc.com |
 |
US regulators tell 23andMe to protect genetic dataApril 1 - Tech Xplore |
 |
Deleting Your 23andMe Account? Some Data Could Still Be SoldMarch 31 - Forbes |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 60M | 20M | 40M | -53M | -32M | -1.728 |
| Q3 '24 | 44M | 22M | 22M | -59M | -57M | -2.316 |
| Q2 '24 | 40M | 20M | 21M | -69M | -68M | -0.120 |
| Q1 '24 | 64M | 37M | 27M | -209M | -208M | -0.110 |
| Q4 '23 | 45M | 25M | 20M | -278M | -276M | -0.160 |
Insider Transactions View All
| HIBBS KATHY L filed to sell 1,252,315 shares at $0.5. May 6 '24 |
| HIBBS KATHY L filed to sell 1,252,315 shares at $0.5. April 19 '24 |
| HIBBS KATHY L filed to sell 1,252,315 shares at $0.5. April 5 '24 |
| HIBBS KATHY L filed to sell 1,252,315 shares at $0.5. March 22 '24 |
| HIBBS KATHY L filed to sell 1,252,315 shares at $0.5. March 11 '24 |
Similar companies
Read more about 23andMe (ME) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, tiktok followers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of 23andMe?
The Market Cap of 23andMe is $13M.
What is the current stock price of 23andMe?
Currently, the price of one share of 23andMe stock is $0.61.
How can I analyze the ME stock price chart for investment decisions?
The ME stock price chart above provides a comprehensive visual representation of 23andMe's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling 23andMe shares. Our platform offers an up-to-date ME stock price chart, along with technical data analysis and alternative data insights.
Does ME offer dividends to its shareholders?
As of our latest update, 23andMe (ME) does not offer dividends to its shareholders. Investors interested in 23andMe should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of 23andMe?
Some of the similar stocks of 23andMe are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.